Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCR2 PET Imaging in Pancreatic Cancer
NCT03851237Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2019
- Primary completion
- Dec 2025
- Modality
- Positron Emission Tomography Imaging
- Countries
- 1
01
Overview
Phase 1, open-label trial of Cu-DOTA-ECL1i in pancreatic ductal adenocarcinoma (PDAC) (3 cohorts), sponsored by Washington University School of Medicine. Primary endpoints: Detection of CCR2 expression in PDAC tumors, Tumor SUVmax prediction of response to standard of care chemotherapy at Day 1 and 2 more. Started Jan 2019; status: completed.
02
Drugs
Cu-DOTA-ECL1i
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03851237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03851237.